Codexis, Inc. (CDXS)
- Previous Close
2.9000 - Open
2.9100 - Bid 2.7900 x 400
- Ask 2.8200 x 400
- Day's Range
2.7500 - 2.9100 - 52 Week Range
1.4500 - 4.9100 - Volume
209,600 - Avg. Volume
574,582 - Market Cap (intraday)
196.85M - Beta (5Y Monthly) 2.03
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1200 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.57
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
www.codexis.comRecent News: CDXS
Performance Overview: CDXS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDXS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDXS
Valuation Measures
Market Cap
196.85M
Enterprise Value
147.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.72
Price/Book (mrq)
2.27
Enterprise Value/Revenue
2.11
Enterprise Value/EBITDA
-3.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-108.69%
Return on Assets (ttm)
-17.70%
Return on Equity (ttm)
-65.89%
Revenue (ttm)
70.14M
Net Income Avi to Common (ttm)
-76.24M
Diluted EPS (ttm)
-1.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
65.12M
Total Debt/Equity (mrq)
18.50%
Levered Free Cash Flow (ttm)
-9.87M